
Cimed & Co.
Family-controlled Brazilian pharmaceutical and consumer health group founded in 1977, maker of Carmed, Cimegripe, and Lavitan, headquartered in Pouso Alegre.
Company Type
private
Founded
1977
Headquarters
Pouso Alegre, Minas Gerais, Brazil
Revenue
R$3.07 billion net revenue (2025)
Employees
Approximately 9,000
Primary Market
Latin America
Shop Cimed & Co. Brands
Disclosure: We may earn commission from purchasesAbout Cimed & Co.
What does Cimed & Co. own?
Cimed & Co. controls Grupo Cimed's pharmaceutical and consumer health businesses, including brands such as Carmed, Cimegripe, and Lavitan, plus a large OTC and generic medicines portfolio and an expanding consumer goods operation.
Is Cimed & Co. publicly traded?
No. It is a privately held, family-controlled holding company with no stock listing. It does publish consolidated financial statements.
Who founded Cimed & Co.?
The group was founded in 1977 by João Adibe Marques de Oliveira in Marília, São Paulo. It is now led by second-generation CEO João Adibe, with third-generation family members entering senior leadership.
Where is Cimed & Co. headquartered?
The group is headquartered in Pouso Alegre, Minas Gerais, Brazil, where its main manufacturing and administrative operations are concentrated.
Who owns Cimed & Co.?
The company is controlled by the Adibe Marques family across three generations. There are no disclosed outside institutional shareholders.
What is Cimed's financial performance?
In 2025 it reported net revenue of approximately R$3.07 billion, up 12.5 percent, and net income of R$196.7 million, down about 30 percent. It reported about R$1 billion in revenue in the first quarter of 2026 and targets R$10 billion annually by 2030.
History of Cimed & Co.
Grupo Cimed was founded in 1977 by João Adibe Marques de Oliveira in Marília, in the interior of São Paulo state. It started as a pharmaceutical distribution and marketing business before expanding into manufacturing its own medicines.
Over the following decades the company industrialized, building production facilities and shifting its center of operations to Pouso Alegre in southern Minas Gerais. It grew on a high-volume model: over-the-counter medicines, generics, and consumer health products sold across Brazil's vast pharmacy network rather than patented specialty drugs.
The company's defining strategic move was consumer brand building. Carmed, Cimegripe, and Lavitan became national household names, giving Cimed a consumer profile rare among Brazilian pharma companies and letting it compete on brand recognition as much as on pharmacy relationships. Sports marketing, especially in Stock Car Brasil, amplified that visibility.
Under second-generation CEO João Adibe, the group expanded deliberately beyond medicines into consumer goods, framing its ambition as becoming Brazil's largest health and consumer company. That strategy combined manufacturing investment, portfolio expansion, and stronger corporate governance.
Recent years brought both growth and strain. In 2025 the company implemented SAP S/4HANA, one of the largest technology projects in its history, which caused temporary commercial disruption before operations recovered from the second quarter. Net revenue still grew 12.5 percent to about R$3.07 billion, roughly double the pharmaceutical sector's growth rate, but profit fell about 30 percent on higher costs. In the first quarter of 2026 it reported roughly R$1 billion in quarterly revenue, up 20 percent year over year, and named third-generation family member Adibe Marques to a vice-president role overseeing operations, people, and growth.
Cimed & Co. Sustainability & Ethics
Cimed's ethics profile is defined by pharmaceutical regulation rather than consumer sustainability certifications. As a Brazilian drugmaker it operates under ANVISA oversight for product registration, good manufacturing practices, and pharmacovigilance, which are the relevant accountability frameworks for its core business.
It holds no documented flagship independent certification such as B Corp status as of November 2026. Its published financial statements and governance investments signal a move toward more formal corporate structure, but its sustainability and ESG reporting is not a prominent public feature of the company at this time.
Controversy, Regulation & Public Scrutiny
Cimed has no dominant public scandal on record as of November 2026. The scrutiny it attracts is mainly financial and operational.
The most discussed recent issue is the 2025 profit decline of about 30 percent despite double-digit revenue growth, which analysts linked to rising costs and the disruptive SAP S/4HANA implementation. Management acknowledged internal limitations and described corrective actions taken through the year. Like other large Brazilian pharma companies it operates in a competitive, regulated market and faces routine ANVISA and commercial scrutiny, but no major product recall or regulatory sanction defined its record at the time of writing.
Brands Owned by Cimed & Co.
Cimed & Co. owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Cimed & Co.
private · Founded 1977 · Pouso Alegre, Minas Gerais, Brazil
1
brands
Cimed & Co. Ownership: Pros & Cons
Advantages
- +Full family control enables long-horizon investment and multi-generational continuity
- +Strong consumer brands create recurring sales and pricing power
- +Domestic manufacturing gives control of supply and production economics
- +A published financial track record provides unusual transparency for a private group
Considerations
- -Family governance concentrates succession and control risk in one family
- -Private status limits access to public equity capital for its expansion plan
- -2025 margin compression showed sensitivity to cost inflation and execution missteps
- -Near-total dependence on the Brazilian market limits geographic diversification
Frequently Asked Questions About Cimed & Co.
What does Cimed & Co. own?
Cimed & Co. controls Grupo Cimed's pharmaceutical and consumer health businesses, including brands such as Carmed, Cimegripe, and Lavitan, plus a large OTC and generic medicines portfolio and an expanding consumer goods operation.
Is Cimed & Co. publicly traded?
No. It is a privately held, family-controlled holding company with no stock listing. It does publish consolidated financial statements.
Who founded Cimed & Co.?
The group was founded in 1977 by João Adibe Marques de Oliveira in Marília, São Paulo. It is now led by second-generation CEO João Adibe, with third-generation family members entering senior leadership.
Where is Cimed & Co. headquartered?
The group is headquartered in Pouso Alegre, Minas Gerais, Brazil, where its main manufacturing and administrative operations are concentrated.
Who owns Cimed & Co.?
The company is controlled by the Adibe Marques family across three generations. There are no disclosed outside institutional shareholders.
What is Cimed's financial performance?
In 2025 it reported net revenue of approximately R$3.07 billion, up 12.5 percent, and net income of R$196.7 million, down about 30 percent. It reported about R$1 billion in revenue in the first quarter of 2026 and targets R$10 billion annually by 2030.







